The SUM-190PT cell line was the second cell line that we developed from a patient with inflammatory breast cancer. Like the SUM-149PT cells, these cells overexpress the CDH1 (E-Cadherin) gene which is one of the defining features of inflammatory breast cancer. Unlike the SUM-149PT cells, this cell line has an amplification and overexpression of the ERBB2 (HER2) oncogene and also a common point mutation in the PIK3CA gene. Since ERBB2 signals through the PI3K/AKT pathway, the presence of an activating mutation in PIK3CA results in these cells being less sensitive to ERBB2 targeted drugs than cell line SUM-225 which harbors an ERBB2 amplification in the absence of PIK3CA mutations.
Okay, let’s delve more deeply into the SUM-190 cell line.
- Characteristics of the patient from which SUM-190 was derived
- Narrative Summary of the SUM-190 Cell Line
- The oncogene signatures of the SUM-190 cell line
- The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
- Functional-druggable signature of the SUM-190 cells
- Bibliography of published papers in which SUM-190 cells were used
- SUM-190 Blog
Back to the SUM cell line Gateway Page
Back to SUM-line Knowledge Base Home page
